Collegium Pharmaceutical
COLL
172 hedge funds and large institutions have $734M invested in Collegium Pharmaceutical in 2022 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 63 increasing their positions, 55 reducing their positions, and 14 closing their positions.
107% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 14
45% more call options, than puts
Call options by funds: $719K | Put options by funds: $497K
15% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 55
10% more capital invested
Capital invested by funds: $668M → $734M (+$65.6M)
8% more funds holding
Funds holding: 159 → 172 (+13)
4.47% more ownership
Funds ownership: 103.63% → 108.09% (+4.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$7.43M |
| 2 |
DZ Bank
Frankfurt Am Main,
Germany
|
+$5.09M |
| 3 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$4.26M |
| 4 |
Morgan Stanley
New York
|
+$3.24M |
| 5 |
State Street
Boston,
Massachusetts
|
+$3.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$26.8M |
| 2 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
-$5.04M |
| 3 |
JG
Jefferies Group
New York
|
-$3.01M |
| 4 |
SDIC
South Dakota Investment Council
Sioux Falls,
South Dakota
|
-$1.42M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$1.17M |
COLL Hedge Fund Activity: Q1 2022 in Review
172 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q1 2022, worth a combined $734M — up 9.8% from $668M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new COLL positions and 14 closed out — a net gain of 15 holders — while 63 added to existing stakes and 55 trimmed.
The largest buyer was Rubric Capital Management (New York), adding an estimated $7.43M. The largest seller was Janus Henderson Group, cutting an estimated $26.8M.
- 172 institutional investors held Collegium Pharmaceutical (COLL) as of Q1 2022, up from 159 in Q4 2021.
- Funds reported $734M of Collegium Pharmaceutical stock for Q1 2022, up 9.8% quarter-over-quarter.
- 29 funds opened new Collegium Pharmaceutical positions in Q1 2022 and 14 closed out, a net change of +15 holders.
- The largest Collegium Pharmaceutical buyer in Q1 2022 was Rubric Capital Management (New York), an estimated $7.43M added.
- The largest Collegium Pharmaceutical seller in Q1 2022 was Janus Henderson Group, an estimated $26.8M sold.
Based on aggregated 13F filings for Q1 2022.